PMID- 30475455
OWN - NLM
STAT- MEDLINE
DCOM- 20190823
LR  - 20200309
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Print)
IS  - 1759-7706 (Linking)
VI  - 10
IP  - 1
DP  - 2019 Jan
TI  - PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using 
      simultaneous genotypic screening of EGFR, ALK, and ROS1.
PG  - 103-110
LID - 10.1111/1759-7714.12917 [doi]
AB  - BACKGROUND: The aim of the current study was to investigate the prevalence and 
      clinicopathologic characteristics of ROS1-rearranged non-small cell lung cancer 
      (NSCLC) in routine genotypic screening in conjunction with the study of PD-L1 
      expression, a biomarker for first-line treatment decisions. METHODS: Reflex 
      simultaneous genotypic screening for EGFR by peptide nucleic acid clamping, and 
      ALK and ROS1 by fluorescence in situ hybridization (FISH) was performed on 
      consecutive NSCLC cases at the time of initial pathologic diagnosis. We evaluated 
      genetic aberrations, clinicopathologic characteristics, and PD-L1 tumor 
      proportion score (TPS) using a PD-L1 22C3 assay kit. RESULTS: In 407 consecutive 
      NSCLC patients, simultaneous genotyping identified 14 (3.4%) ROS1 and 19 (4.7%) 
      ALK rearrangements, as well as 106 (26%) EGFR mutations. These mutations were 
      mutually exclusive and were found in patients with similar clinical features, 
      including younger age, a prevalence in women, adenocarcinoma, and advanced stage. 
      The PD-L1 assay was performed on 130 consecutive NSCLC samples. High PD-L1 
      expression (TPS >/= 50%) was observed in 29 (22.3%) tumors. PD-L1 expression 
      (TPS >/= 1%) was significantly associated with wild type EGFR, while ROS1 
      rearrangement was associated with high PD-L1 expression. Of the 14 cases with 
      ROS1 rearrangement, 12 (85.7%) showed PD-L1 expression and 5 (35.7%) showed high 
      PD-L1 expression. CONCLUSION: In the largest consecutive routine Asian NSCLC 
      cohort analyzed to date, we found that high PD-L1 expression frequently 
      overlapped with ROS1 rearrangement, while it negatively correlated with EGFR 
      mutations.
CI  - (c) 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and 
      John Wiley & Sons Australia, Ltd.
FAU - Lee, Jongmin
AU  - Lee J
AD  - Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal 
      Medicine, College of Medicine, The Catholic University of Korea, Seoul, South 
      Korea.
FAU - Park, Chan Kwon
AU  - Park CK
AD  - Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal 
      Medicine, College of Medicine, The Catholic University of Korea, Seoul, South 
      Korea.
FAU - Yoon, Hyoung-Kyu
AU  - Yoon HK
AD  - Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal 
      Medicine, College of Medicine, The Catholic University of Korea, Seoul, South 
      Korea.
FAU - Sa, Young Jo
AU  - Sa YJ
AD  - Department of Thoracic and Cardiovascular Surgery, College of Medicine, The 
      Catholic University of Korea, Seoul, South Korea.
FAU - Woo, In Sook
AU  - Woo IS
AD  - Division of Hematology-Oncology, Department of Internal Medicine, College of 
      Medicine, The Catholic University of Korea, Seoul, South Korea.
FAU - Kim, Hyo Rim
AU  - Kim HR
AD  - Department of Radiology, College of Medicine, The Catholic University of Korea, 
      Seoul, South Korea.
FAU - Kim, Sue Youn
AU  - Kim SY
AD  - Department of Hospital Pathology, Yeouido St. Mary Hospital, College of Medicine, 
      The Catholic University of Korea, Seoul, South Korea.
FAU - Kim, Tae-Jung
AU  - Kim TJ
AUID- ORCID: 0000-0003-3140-3681
AD  - Department of Hospital Pathology, Yeouido St. Mary Hospital, College of Medicine, 
      The Catholic University of Korea, Seoul, South Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181126
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD274 protein, human)
RN  - 0 (Proto-Oncogene Proteins)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (ROS1 protein, human)
MH  - Adult
MH  - Aged
MH  - Anaplastic Lymphoma Kinase/genetics
MH  - B7-H1 Antigen/*genetics
MH  - Biomarkers, Tumor/genetics
MH  - Carcinoma, Non-Small-Cell Lung/diagnosis/*genetics/pathology
MH  - Early Detection of Cancer
MH  - ErbB Receptors/genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Rearrangement/genetics
MH  - Genotype
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Protein-Tyrosine Kinases/*genetics
MH  - Proto-Oncogene Proteins/*genetics
PMC - PMC6312846
OTO - NOTNLM
OT  - Biomarker
OT  - epidermal growth factor receptor
OT  - human ROS1 protein
OT  - non-small cell lung carcinoma
OT  - programmed death 1 ligand 1
EDAT- 2018/11/27 06:00
MHDA- 2019/08/24 06:00
PMCR- 2019/01/01
CRDT- 2018/11/27 06:00
PHST- 2018/09/18 00:00 [received]
PHST- 2018/10/21 00:00 [revised]
PHST- 2018/10/21 00:00 [accepted]
PHST- 2018/11/27 06:00 [pubmed]
PHST- 2019/08/24 06:00 [medline]
PHST- 2018/11/27 06:00 [entrez]
PHST- 2019/01/01 00:00 [pmc-release]
AID - TCA12917 [pii]
AID - 10.1111/1759-7714.12917 [doi]
PST - ppublish
SO  - Thorac Cancer. 2019 Jan;10(1):103-110. doi: 10.1111/1759-7714.12917. Epub 2018 
      Nov 26.